EU clears daily weight-loss pill Wegovy

For millions of Europeans living with obesity, the weekly injection was the catch. Semaglutide, the drug behind Wegovy and Ozempic, has made drug treatment for obesity a mainstream medical conversation. But many patients never started because they couldn't face the needle. The European Commission has now authorised a daily Wegovy pill, approved for adults with obesity or overweight with at least one weight-related health condition.

A pill sounds like the simpler option. The chemistry behind it tells a different story.

Getting a Protein Past Your Stomach

Semaglutide mimics a gut hormone called GLP-1 that your body releases after eating. It turns up your own fullness signals, slows digestion and dampens appetite over time. Think of it not as a fat burner, but as a volume knob on satiety. In a peer-reviewed trial published in The Lancet, oral semaglutide produced an average 15.1% body weight loss at 68 weeks, versus 2.4% on placebo.

The catch is that semaglutide is a peptide, a protein-like chain, and your stomach is built to shred those. Acid and enzymes destroy peptides before they can reach the bloodstream, which is why GLP-1 drugs arrived as injections first. The pill uses a compound called SNAC that creates a temporary shield around the drug, letting a small fraction slip through the stomach lining. It works, but the shield is fragile. You have to swallow the tablet on an empty stomach, first thing in the morning, with only a small sip of water, then wait at least 30 minutes before eating, drinking or taking other medicines.

That trade-off is real. A weekly injection is unpleasant but infrequent. A daily pill avoids the needle but demands a morning ritual easily disrupted by coffee, breakfast, shift work or forgetfulness. The side effects, mainly nausea and digestive discomfort, are similar regardless of how the drug enters your body. This is a new option, not necessarily an easier one.

27 Countries, 27 Price Tags

EU approval is permission to sell, not a promise that public insurance will pay. Each member state decides separately whether to reimburse the drug, for whom and at what price. Europe will not get one Wegovy pill market; it will get many national versions of access.

France began reimbursing the injectable version at 65% in mid-June 2026, but only for severe obesity, after documented failure of diet-based treatment, and only when initiated by a specialist. The oral pill has no French price listing yet.

Germany may be tougher. Weight-management drugs can be classified as lifestyle products and excluded from statutory insurance, even when obesity carries serious health consequences. Sweden is bluntest: its national pricing authority refused to include Wegovy in its subsidy scheme in February 2026, ruling that Novo Nordisk hadn't demonstrated reasonable cost. Strong clinical results were not enough.

Denmark, predictably, celebrated the approval as a milestone for its pharmaceutical national champion. Independent analysis suggests the oral format gives Novo a head start over Eli Lilly, whose competing oral products aren't expected until around 2027.

What Comes After the First Pill

That competition may matter more than any single approval. Lilly's oral candidate, orforglipron, is built differently: a small synthetic molecule rather than a protein chain. Because it doesn't need the same biological shielding to survive the stomach, analysts expect it could be cheaper to manufacture and free of the strict fasting rules that make semaglutide tablets so demanding. The contest will turn on convenience, manufacturing cost and reimbursement.

A broader caution applies. A review highlighted by Science Media Centre España warned that obesity-drug decisions should weigh quality of life, safety and treatment burden, not just kilograms lost. GLP-1 drugs also sit on an uncomfortable line between treating a chronic disease and serving consumer demand for thinness, a tension German and Dutch health authorities are already navigating.

The Wegovy pill is genuine progress: a powerful drug class made accessible to people who would never accept an injection. But for most Europeans, the pill's real approval will happen country by country, at the reimbursement desk.